## Miren GarcÃ-a Cortes

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7377368/publications.pdf

Version: 2024-02-01

37 papers

2,154 citations

393982 19 h-index 276539 41 g-index

45 all docs

45 docs citations

45 times ranked

1811 citing authors

#	Article	IF	Citations
1	Herbal and Dietary Supplements-Induced Liver Injury in Latin America: Experience From the LATINDILI Network. Clinical Gastroenterology and Hepatology, 2022, 20, e548-e563.	2.4	21
2	Safety of treating acute liver injury and failure. Expert Opinion on Drug Safety, 2022, 21, 191-203.	1.0	6
3	Differential iNKT and T Cells Activation in Non-Alcoholic Fatty Liver Disease and Drug-Induced Liver Injury. Biomedicines, 2022, 10, 55.	1.4	4
4	Management of Pharmacologic Adverse Effects in Advanced Liver Disease. Clinical Drug Investigation, 2022, 42, 33-38.	1.1	3
5	Microbiota diversity in nonalcoholic fatty liver disease and in drug-induced liver injury. Pharmacological Research, 2022, 182, 106348.	3.1	29
6	Clinical Characteristics and Outcome of Drugâ€Induced Liver Injury in the Older Patients: From the Youngâ€Old to the Oldestâ€Old. Clinical Pharmacology and Therapeutics, 2021, 109, 1147-1158.	2.3	16
7	Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry. Journal of Hepatology, 2021, 75, 86-97.	1.8	72
8	Lymphocyte Profile and Immune Checkpoint Expression in Drugâ€Induced Liver Injury: An Immunophenotyping Study. Clinical Pharmacology and Therapeutics, 2021, 110, 1604-1612.	2.3	15
9	Incidence and prevalence of acute hepatitis E virus infection in patients with suspected Drugâ€Induced Liver Injury in the Spanish DILI Registry. Liver International, 2020, 41, 1523-1531.	1.9	10
10	Drug induced liver injury: an update. Archives of Toxicology, 2020, 94, 3381-3407.	1.9	125
11	Drug-induced liver injury in older people. The Lancet Gastroenterology and Hepatology, 2020, 5, 862-874.	3.7	42
12	Drugâ€Induced Liver Injury After Liver Transplantation. Liver Transplantation, 2020, 26, 1167-1176.	1.3	10
13	Liver injury after methylprednisolone pulses: A disputable cause of hepatotoxicity. A case series and literature review. United European Gastroenterology Journal, 2019, 7, 825-837.	1.6	29
14	Enfermedad hepática por alcohol. GuÃas de práctica clÃnica. Documento de consenso auspiciado por la AEEH. GastroenterologÃa Y HepatologÃa, 2019, 42, 657-676.	0.2	12
15	Hepatic Damage by Natural Remedies. Seminars in Liver Disease, 2018, 38, 021-040.	1.8	33
16	Documento de consenso. Manejo de la enfermedad hepática grasa no alcohólica (EHGNA). GuÃa de práctica clÃnica. GastroenterologÃa Y HepatologÃa, 2018, 41, 328-349.	0.2	71
17	Herbal and Dietary Supplement-Induced Liver Injuries in the Spanish DILI Registry. Clinical Gastroenterology and Hepatology, 2018, 16, 1495-1502.	2.4	83
18	Drug-induced liver injury: a safety review. Expert Opinion on Drug Safety, 2018, 17, 795-804.	1.0	31

#	Article	IF	CITATIONS
19	Outbreak of acute hepatitis A in the health area served by the Hospital Universitario Virgen de la Victoria (HUVV): a change in epidemiology. Revista Espanola De Enfermedades Digestivas, 2018, 110, 380-385.	0.1	6
20	Hepatotoxicity by Dietary Supplements: A Tabular Listing and Clinical Characteristics. International Journal of Molecular Sciences, 2016, 17, 537.	1.8	114
21	Killer Immunoglobulin-Like Receptor Profiles Are not Associated with Risk of Amoxicillin-Clavulanate–Induced Liver Injury in Spanish Patients. Frontiers in Pharmacology, 2016, 7, 280.	1.6	3
22	Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury. Journal of Hepatology, 2016, 65, 532-542.	1.8	115
23	The value of serum aspartate aminotransferase and gammaâ€glutamyl transpetidase as biomarkers in hepatotoxicity. Liver International, 2015, 35, 2474-2482.	1.9	47
24	Distinct phenotype of hepatotoxicity associated with illicit use of anabolic androgenic steroids. Alimentary Pharmacology and Therapeutics, 2015, 41, 116-125.	1.9	95
25	Causality Assessment. , 2013, , 287-302.		1
26	Causality assessment methods in drug induced liver injury: Strengths and weaknesses. Journal of Hepatology, 2011, 55, 683-691.	1.8	164
27	¿Debemos seguir usando un inhibidor de la bomba de protones en pacientes con cardiopatÃa isquémica y doble antiagregación plaquetaria?. Cardiocore, 2010, 45, 79-82.	0.0	0
28	Phenotypic characterization of idiosyncratic drug-induced liver injury: The influence of age and sex. Hepatology, 2009, 49, 2001-2009.	3.6	266
29	Assessment of drugâ€induced liver injury in clinical practice. Fundamental and Clinical Pharmacology, 2008, 22, 141-158.	1.0	66
30	Evaluation of Naranjo Adverse Drug Reactions Probability Scale in causality assessment of drugâ€induced liver injury. Alimentary Pharmacology and Therapeutics, 2008, 27, 780-789.	1.9	150
31	Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry. Hepatology, 2006, 44, 1581-1588.	3.6	267
32	Is the Naranjo Probability Scale Accurate Enough to Ascertain Causality in Drug-Induced Hepatotoxicity?. Annals of Pharmacotherapy, 2004, 38, 1540-1541.	0.9	19
33	HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease. Hepatology, 2004, 39, 1603-1612.	3.6	134
34	Acute leukemia after infliximab therapy. American Journal of Gastroenterology, 2003, 98, 2577.	0.2	7
35	Lansoprazole-Induced Hepatic Dysfunction. Annals of Pharmacotherapy, 2003, 37, 1731-1731.	0.9	6
36	Cholestatic hepatitis related to use of irbesartan: a case report and a literature review of angiotensin II antagonist-associated hepatotoxicity. European Journal of Gastroenterology and Hepatology, 2002, 14, 887-890.	0.8	45

## MIREN GARCÃA CORTES

#	Article	IF	CITATIONS
37	Unusual duodenal duplication cyst associated with partial gastric diverticulum in a middle-aged woman: are they congenital or acquired?. Digestive Diseases and Sciences, 2002, 47, 304-308.	1.1	3